Over 88% Of Wegovy Trial Participants Achieve Normal Liver Fat Levels, Novo Reports - Novo Nordisk (NYSE:
Novo Nordisk reported that 88.5% of Wegovy trial participants achieved normal liver fat levels. The analysis of 55 participants showed mean liver fat decreased from 8.8% to 3.1% over 72 weeks. The study pooled 1,919 adults from STEP UP and STEP UP T2D trials, with over 94% at high risk for fatty liver. NVO shares were down 0.46% at $37.73.
How this was made
The 30-second read
Why it matters
Positive trial data could support future label expansion and strengthen the drug's market position.
Market read
New clinical data may influence investor sentiment on Novo Nordisk and the broader GLP‑1 market.
What to watch
Regulatory pathways for semaglutide 2.4 mg in MASH and competitive pipeline developments.
Background
Novo Nordisk's Wegovy is approved for obesity; the company is exploring semaglutide 2.4 mg for MASH treatment.
Ticker impact
Novo Nordisk disclosed post‑hoc STEP UP trial data showing Wegovy reduced liver fat to normal levels in 88% of participants.
modest upside pressure as investors reassess obesity‑treatment potential
Data is positive but sample size is small and shares were already slightly down at release.
Market effects
Potential boost for obesity‑treatment and GLP‑1 drug sector.
Limited to markets where Wegovy is approved.
Modest relevance for global pharma investors.
Counterpoint
Small sample and post‑hoc nature may limit clinical significance; investors may remain cautious.
Key entities
- companyNovo Nordisk A/S
Pharmaceutical company reporting the trial results.
- productWegovy (semaglutide)
Obesity drug evaluated for liver‑fat reduction.
